Grail plans FDA filing for cancer blood test after new trial
Grail is eyeing FDA approval of its Galleri cancer screening blood test after a second positive phase 3 trial.
Dupixent is first FDA-approved drug for rare skin disease
The long list of therapeutic uses for Sanofi and Regeneron's Dupixent has been lengthened by an FDA approval for rare skin disease bullous pemphigoid.
FDA blocks trials that send US cells to 'hostile' countries
The FDA says it will review clinical trials that send US citizens' cells to 'hostile countries' as the agency's leadership in this area is sidelined.
Could a Novo error set up early GLP-1 generics in Canada?
Reports say Novo Nordisk may have inadvertently let generics of its GLP-1 drug semaglutide for diabetes and obesity launch in Canada early next year.
Latest News
Views & Analysis
Deep Dive
White Papers & Webinar
Podcasts & Video
Partner Content
16th World ADC San Diego 2025
The World’s Largest, Longest-Standing & Most Comprehensive Antibody-Drug Conjugate Conference
EVERSANA expands commercialisation portfolio with OS Therapi...
EVERSANA, a leading provider of global commercial services to the life sciences industry, has announced two strategic partnerships to support the US commercialisation of innovative therapies from O
The Pharmaceutical Marketing Society and the Chartered Insti...
The PM Society is delighted to announce a new partnership with the CIM to build capability and excellence in marketing in the pharmaceutical industry.
15th World Clinical Biomarkers & Companion Diagnostics Summi...
The biomarkers and diagnostics field continues to boom, driven by advancements in genomic profiling, omics, and AI technologies.
5th iPSC Drug Development Summit
Advance iPSC therapies from bench to bedside with 30+ industry experts at this year’s summit.